Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Raplixa in pediatric surgical hemostasis
NCT02117349Phase 2Terminated
- Sponsor
- Mallinckrodt Pharmaceuticals
- Start
- Dec 2014
- Primary completion
- Nov 2017
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of fibrinogen + thrombin (2 arms), sponsored by Mallinckrodt Pharmaceuticals. Primary endpoint: Number of Participants Who Reached Hemostasis at the Target Bleeding Site (TBS) Within 4 Minutes. Started Dec 2014; status: terminated.
02
Drugs
fibrinogen + thrombin
Beyond the preview
Go deeper on NCT02117349.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02117349.